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ABSTRACT Objective: To investigate whether vitamin D receptor gene (VDR) BsmI-rs1544410 and FokI-rs2228570 polymorphisms, smoking
duration, and body mass index (BMI) are risk factors for cutaneous melanoma, especially metastatic melanoma.
Methods: We studied 120 cutaneous melanoma cases [68 stage I and II non-metastatic melanoma (NMetM) patients, plus 52
Stage  III  and  IV  metastatic  melanoma (MetM)  patients],  and  120  matching  healthy  controls  from northeast  Italy.  VDR
polymorphisms were measured by restriction fragment length polymorphism analysis. Absence or presence of BsmI and FokI
restriction sites was denoted by “B” and “F” or by “b” and “f,” respectively.
Results: VDR-BsmI bb genotype was more frequent among MetM (32.7%) than among NMetM cases (13.2%), with odds ratio
(OR)=3.18. Comparison of all melanoma patients vs healthy controls showed that the following biomarkers were at risk: ≥20 years
of  smoking (OR=2.43);  ≥20 years  of  smoking combined with bb (OR=4.78),  Bb+bb (OR=2.30),  Ff  (OR=3.04),  and Ff+ff
(OR=3.08); obesity (BMI>30 kg/m2) alone (OR=3.54); and obesity combined with Bb+bb (OR=3.52), Ff (OR=4.78), and Ff+ff
(OR=6.56). Comparison of MetM vs NMetM patients revealed that the following biomarkers were at risk: ≥20 years of smoking
(OR=2.39), ≥20 years of smoking combined with bb (OR=5.13), Bb+bb (OR=3.07), and Ff+ff (OR=2.66); and obesity combined
with Bb+bb (OR=5.27), Ff (OR=6.28), and Ff+ff (OR=9.18). Triple combination of ≥20 years of smoking, obesity, and Bb+bb
yielded OR=9.65 for melanoma patients vs healthy controls and OR=12.2 for MetM vs. NMetM patients.
Conclusions: Risk factors for cutaneous MetM include two VDR polymorphisms combined with smoking duration and obesity.
Results suggest gene-environment implications in melanoma susceptibility and severity. Future studies in larger cohorts and in
subjects with different genetic background are warranted to extend our findings.
KEYWORDS Vitamin D receptor; VDR polymorphism; cutaneous melanoma; metastatic melanoma; smoking; body mass index; obesity; skin
cancer
 
Introduction
Melanoma  continually  presents  increased  incidence  in  all
developed  countries,  particularly  affecting  fair-skinned
individuals1-3.  Malignant  melanoma  more  frequently  occurs
in  northern  than  in  southern  European  countries3.
Melanoma more frequently affects both sexes in Switzerland
(European  age  standardized  incidence  rate  25.8/
100,000/year)  and Slovenia  (20.6/100,000/year)  than in  Italy
(13.4/100,000/year)4.  Recent  data  in  Italy5  indicated  a  more
than  doubled  prevalence  of  melanoma  in  northern  than
southern  Italy,  with  central  Italy  presenting  an  intermediate
value.  Specifically,  high  incidence  rates  were  recorded  in
Friuli-Venezia  Giulia  (FVG)  region  (19.6/100,000/year  in
men;  16.4/100,000/year  in  women)  in  northeast  Italy6.  This
finding  implies  necessity  for  conducting  geographically
detailed  studies  regarding  melanoma  risk  factors7.  In  the
present study, we focused on inhabitants of the FVG region.
Critical environmental risk factors for melanoma include
exposure  to  ultraviolet  (UV)  radiation,  especially
intermittent sun exposure and sunburns8,9. However, chronic
and  continuous  UV  ray  exposure  may  yield  protective
effects9,10 at least in part by activating synthesis of vitamin D,
whose  action  is  mediated  by  nuclear  vitamin  D receptor
(VDR). Vitamin D-activated VDR may in turn up- or down-
regulate several hundreds of genes by binding to vitamin D
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responsive  elements  (VDREs),  thus  affecting  several
biological activities, such as calcium metabolism, immunity,
detoxification,  oxidative  stress,  cell  proliferation,  and
differentiation9-12. Increasing evidence showed that vitamin
D reduces risk of numerous types of cancer12. Thus, vitamin
D endocrine system in studies concerning melanoma gained
increasing attention10,13,14. Current studies and meta-analyses
evaluated  the  role  of  the  VDR  gene  (VDR)  polymor-
phisms12-22.  Nonetheless,  VDR  polymorphisms’  roles  still
require further study12,14,21.
The  role  of  smoking  in  melanoma  piqued  interest  of
researchers23,24.  Smoking  is  considered  a  risk  factor  for
malignancies25.  Paradoxically,  several  studies  discovered
inverse  associations  between  smoking  exposure  and
melanoma  after  controlling  for  potential  confounding
variables24,26,27. However, such protective effects are weak or
insignificant28,29.  Other  studies  did  not  confirm  such
association30,31 or demonstrated tendencies toward smoking-
related  increased  risks10,32.  Thus,  pathophysiological
pathways underlying the relationship of smoking and mela-
noma currently poses a challenge in melanoma research23,24.
Some studies on melanoma aimed to determine the role of
body mass index (BMI) in occurrence of the disease9,10,33-35.
However,  limited  research  discusses  combination  of  this
biomarker with genetic traits.
Development in understanding of melanoma risk factors,
genomics, and molecular pathogenesis may drive advances in
precision medicine applied to melanoma2,13,14.
Human VDR gene is located in chromosome 12q12-q14
and comprises 11 exons and 11 introns18-22.  Most clinical
studies  that  explored association of  VDR  polymorphisms
with diseases12,15,18,22 focused on two VDR single-nucleotide
polymorphisms  (SNPs),  namely,  BsmI-rs1544410  G>A
located in intron 8 and FokI-rs2228570 C>T located in exon
2. These two polymorphisms show no linkage disequilibrium
(LD)18,22.
We explored VDR  BsmI-rs1544410 and FokI-rs2228570
SNPs separately, and their association with lifestyle factors,
particularly  smoking  duration  and  BMI  of  patients  with
cutaneous  malignant  melanomas,  specifically  those  with
metastatic melanoma (MetM) vs. non-metastatic melanoma
(NMetM) and vs. healthy controls.
Patients and methods
Population
Enrollment  and  clinical  visits  of  all  study  participants  were
performed  at  Dermatology  Clinic,  University  Hospital  of
Udine.  Diagnostic  procedures  were  carried  out  according  to
routine  protocols.  The  Udine  Institutional  Ethical
Committee  approved  the  study  protocol,  which  was
conducted  according  to  the  Declaration  of  Helsinki.  All
participants  were  alive  during  enrollment  in  the  study  and
signed a written informed consent.
Using  a  case-control  design,  the  study  consecutively
enrolled 120 (65 males and 55 females, age range of 31–84
years) unrelated patients (hospitalized or outpatients) with
documented cutaneous  melanoma diagnosis  and 120 (65
males  and  55  females,  age  range  of  31–84  years)
asymptomatic  healthy  controls,  which  were  matched  for
gender, ancestry, and age with melanoma cases. Inclusion
criteria for both melanoma cases and healthy controls were as
follows: resident in FVG region, at least two grandparents
born in FVG region (or Austro-Hungarian territory before
World  War  I),  and  two  grandparents,  at  the  most,  with
central or southern Italian ancestry. Exclusion criteria for
controls  included  the  following:  any  kind  of  lifelong
malignant or benign tumor, first-grade relatives with history
of  melanoma,  and  major  chronic  diseases,  such  as
autoimmune diseases, type 1 diabetes, and thyroid diseases.
Melanoma  was  diagnosed  using  immunohistological
findings obtained after surgical excision of nevi with clinical
and  dermoscopic  characteristics  suggesting  presence  of
malignancy.  Classification  of  melanoma  stages  was
performed by clinical/histological/radiological findings, as
described in final version of 2009 AJCC36. Inclusion criteria
for case patients comprised cutaneous melanomas that were
more severe than in situ only and with a Clark-grade invasion
over  I.  For  patients  with  multiple  melanomas,  the  major
melanoma  characteristics  were  accounted  for  in  study
analyses  according  to  histological  assessment  of  major
primary tumor (T) grading.
Each participant answered a questionnaire, which was used
to collect data on demographic characteristics, medical and
family  history  of  melanoma,  smoking  habits,  alimentary
habits, and history of sunburns. Phototype was assessed by
Fitzpatrick criteria37.  BMI was determined by weight (kg)
divided  by  squared  height  (m2);  BMI>30  kg/m2  was
considered as an indicator of obesity.
Genetic analysis of VDR polymorphisms
VDR-BsmI  G>A  and  VDR-FokI  C>T  polymorphisms  were
determined,  as  described  in  Refs.38,39,  after  extraction  of
genomic  DNA  from  ethylenediaminetetraacetic-acid-treated
venous  blood  samples40.  Genotypes  were  designated
according  to  absence/presence  of  the  BsmI  or  FokI  enzyme
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restriction  site  by  a  capital  letter  B  allele,  or  F  allele  for
absence,  and  by  a  lowercase  letter  b  allele,  or  f  allele  for
presence,  respectively41.  FokI  and  BsmI  polymorphisms  of
VDR were studied using previously tested primers38-40, which
were  used  to  amplify  appropriate  DNA  fragments.  The
following  primers  were  specifically  used:  FokI-forward  (5′-
AGC  TGG  CCC  TGG  CAC  TGA  CTC  TGC  TCT-3′)  and
FokI-reverse  (5′-ATG GAA ACA CCT TGC TTC TTC TCC
CTC-3′);  BsmI-forward (5′-CAA CCA AGA CTA CAA GTA
CCG  CGT  CAG  TGA-3′)  and  BsmI-reverse  (5′-AAC  CAG
CGG  GAA  GAG  GTC  AAG  GG-3′)  primers.  FokI  enzyme
(Euroclone,  Milano,  Italy)  digestion  of  amplified  265  bp
DNA  fragment  resulted  in  two  196  and  69  bp  fragments  in
the presence of f allele40. To analyze BsmI polymorphism, the
resulting amplified 825 bp fragment was digested with BsmI
restriction enzyme (Euroclone, Milano, Italy), generating two
fragments of 650 and 175 bp in the presence of b allele39.
Statistical analysis
Continuous  variables  were  expressed  as  mean  ±  standard
deviation,  and  Mann-Whitney  U  test  was  performed  for
comparison. Odds ratios (ORs) and 95% confidence intervals
(CIs)  were  calculated  for  categorical  variables,  and  P  values
for  two-sided  Pearson’s  Chi-squared  or  Fisher’s  exact  test
were reported as appropriate. Logistic regression was used to
evaluate  effects  of  confounders  by  obtaining  adjusted  ORs
and  CIs.  Five  different  combinations  of  confounders  were
tested.  Adjusted  analysis  included  conventional  risk  factors:
(1)  gender  and  age;  (2)  gender,  age,  phototype  1+2,  total
number  of  body  nevi>50,  and  number  of  lifelong
sunburns>10.  To  compare  MetM  and  NMetM,  adjusted
analyses included indicators that resulted in risk of metastasis
development: (3) trunk location, Breslow’s thickness, ulcera-
tion,  mitosis>1,  absence  of  tumor-infiltrating  lymphocytes
(TILs), and epithelioid variant; (4) ≥20 years of smoking; and
(5) BMI>30 kg/m2  (i.e., obesity). Adjusted analysis of type 3
confounders  involved  factors  associated  (according  to  our
findings)  with  ≥20 years  of  smoking.  These  factors  included
TIL absence, ulceration and obesity. Thus, to avoid overcor-
rection,  combined  categorical  variables,  including  smoking
and obesity, were not adjusted for type 3 confounders.
Tests for deviations from Hardy-Weinberg equilibrium
(HWE)  were  separately  performed  using  chi-square
distribution  for  each  SNP39,40.  LD  between  SNPs  was
determined as described by Colombini et al.39
A two-sided value of P<0.05 was considered significant,
and P≤0.10 indicates tendency to be significant. Statistical
software SPSS for Windows (SPSS Inc., Chicago, IL, USA)
was used.
Results
All  240  (120  cutaneous  melanoma  patients  +  120  healthy
controls)  study  subjects  were  Italian  white  residents  in  the
FVG region.
Primary clinical characteristics of melanoma
patients
As  reported  in  Table  1,  we  examined  in  detail  differences
between  MetM  and  NMetM  patients  to  also  identify
appropriate  variables  to  be  included  as  confounders  in
subsequent  multivariate  analyses.  Frequency  of  young  (<40
years old) or old (≥60 years old) melanoma patients at study
enrolment did not differ between MetM and NMetM groups
(mean  age  comparisons  reported  in  Table  2).  Mean  age  at
melanoma  diagnosis  reached  53.1±13.26  years.  Mean  time
for  melanoma  diagnosis  totaled  6.5±3.58  years  and  did  not
differ between MetM and NMetM patients.
The  majority  of  68  NMetM  patients  were  in  stage  I
(70.6%), whereas the majority of 52 MetM patients were in
stage  III  (65.4%).  Location  in  the  trunk  (OR=0.35)  and
superficial spreading (OR=0.31) showed protective effects for
MetM  patients  vs.  NMetM  patients.  Mean  Breslow’s
thickness doubled in MetM cases vs. NMetM cases (2.8±1.74
vs. 1.4±1.34 mm, P<0.001). Specifically, a Breslow’s thickness
≤0.75  mm  had  protective  effects  (OR=0.06),  whereas
thickness  ≥4.01  mm  was  risky  (OR=9.90)  for  MetM  vs.
NMetM  cases.  Some  biomarkers  were  more  frequently
observed  in  MetM  than  in  NMetM  patients.  These
biomarkers  included  Clark  IV  invasion  (OR=4.38),
ulceration (OR=3.79), mitosis >1 (OR=3.77), TIL absence
(OR=2.20), and epithelioid variant (OR=2.98).
Obesity and smoking history
By  comparing  obese  and  non-obese  melanoma  patients,  we
observed that non-brisk TIL cases were less frequent in obese
(1/16,  6.25%)  than  in  non-obese  (40/104,  38.5%)  patients,
with OR=0.11, 95% CI=0.01–0.84, and P=0.011. By contrast,
TIL absence was more frequent in obese (10/16, 62.5%) than
in  non-obese  (31/104,  29.8%)  melanoma  patients,  resulting
in OR=3.92, 95% CI=1.31–11.7, and P=0.010.
Similar findings were observed by comparing melanoma
patients who smoked ≥20 years vs. the remaining melanoma
patients. Frequency of non-brisk TIL cases was lower in ≥20-
year smokers (7/36, 19.4%) than other melanoma patients
(34/84, 40.5%), yielding OR=0.35, 95% CI=0.14–0.90, and
P=0.026. By contrast, TIL absence was more frequent in ≥20-
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Table 1   Clinical characteristics of 120 consecutively enrolled melanoma patients and comparison between the two subgroups of 52 MetM
and 68 NMetM patients
Characteristics All melanomapatients (n=120) MetM (n=52) NMetM (n=68)
OR (CI) (MetM vs.
NMetM)
P (MetM vs.
NMetM)
Age, years, n (%)
　<40 9 (7.5) 3 (5.8) 6 (8.8) 0.63 (0.15–2.66) 0.730
　≥ 60 60 (50.0) 27 (51.9) 33 (48.5) 1.14 (0.56–2.36) 0.713
Age at melanoma diagnosis
(years, mean±SD)
53.1±13.26 53.9±13.01 52.5±13.51 – 0.569a
Time from melanoma
diagnosis (years, mean±SD)
6.5±3.58 6.3±4.13 6.6±3.08 – 0.344a
Stage, n (%)
　I 48 (40.0) 0 (–) 48 (70.6) –b –b
　II 20 (16.7) 0 (–) 20 (29.4) –b –b
　III 34 (28.3) 34 (65.4) 0 (–) –b –b
　IV 18 (15.0) 18 (34.6) 0 (–) –b –b
Trunk, n (%) 68 (56.7) 22 (42.3) 46 (67.6) 0.35 (0.17–0.74) 0.006
Upper limb, n (%) 8 (6.7) 2 (3.8) 6 (8.8) 0.41 (0.08–2.14) 0.463
Lower limb, n (%) 26 (21.7) 15 (28.8) 11 (16.2) 2.10 (0.87–5.07) 0.095^
Hands/feet, n (%) 8 (6.7) 6 (11.5) 2 (2.9) 4.30 (0.83–22.3) 0.076^
Head/neck, n (%) 10 (8.3) 7 (13.5) 3 (4.4) 3.37 (0.83–13.7) 0.099^
Superficial spreading, n (%) 56 (46.7) 16 (30.8) 40 (58.8) 0.31 (0.14–0.67) 0.002
Nodular, n (%) 47 (39.2) 25 (48.1) 22 (32.4) 1.94 (0.92–4.07) 0.080^
Acral lentiginous, n (%) 5 (4.2) 4 (7.7) 1 (1.5) 5.58 (0.60–51.5) 0.165
Lentigo maligna, n (%) 2 (1.7) 1 (1.9) 1 (1.5) 1.31 (0.08–21.5) 1.000
Spitzoide, n (%) 5 (4.2) 2 (3.8) 3 (4.4) 0.87 (0.14–5.38) 1.000
Others, n (%) 8 (6.7) 6 (11.5) 2 (2.9) 4.30 (0.83–22.3) 0.076^
Breslow thickness
(mm, mean±SD)
2.0±1.66 2.8±1.74 1.4±1.34 – <0.001a
Breslow thickness
≤0.75 mm, n (%)
28 (23.3) 2 (3.8) 26 (38.2) 0.06 (0.01–0.29) <0.001
Breslow thickness
≥4.01 mm, n (%)
14 (11.7) 12 (23.1) 2 (2.9) 9.90 (2.11–46.5) 0.001
Clark II, n (%) 29 (24.2) 4 (7.7) 25 (36.8) 0.14 (0.05–0.44) <0.001
Clark III, n (%) 20 (16.7) 4 (7.7) 16 (23.5) 0.27 (0.08–0.87) 0.021
Clark IV, n (%) 64 (53.3) 38 (73.1) 26 (38.2) 4.38 (2.00–9.60) <0.001
Clark V, n (%) 5 (4.2) 4 (7.7) 1 (1.5) 5.58 (0.60–51.5) 0.165
Ulceration, n (%) 48 (40.0) 30 (57.7) 18 (26.5) 3.79 (1.75–8.18) 0.001
Mitosis >1, n (%) 81 (67.5) 43 (82.7) 38 (55.9) 3.77 (1.59–8.94) 0.002
Regression, n (%) 16 (13.3) 4 (7.7) 12 (17.6) 0.39 (0.12–1.28) 0.112
Brisk positive TILsc, n (%) 37 (30.8) 12 (23.1) 25 (36.8) 0.52 (0.23–1.16) 0.108
Non-brisk TILsc, n (%) 41 (34.2) 16 (30.8) 25 (36.8) 0.76 (0.35–1.65) 0.493
Continued
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Table 2   Comparison of demographic characteristics of 120 melanoma patients and 120 healthy controls and comparison between the two
subgroups of 52 MetM and 68 NMetM patients
Characteristics
All
melanoma
cases
n=120
Healthy
controls
n=120
OR (CI)
(melanomas vs.
healthy
controls)
P
(melanomas
vs. healthy
controls)
MetM
n=52
NMetM
n=68
OR (CI)
(MetM vs.
NMetM)
P (MetM
vs.
NMetM)
Age, years, mean±SD 59.1±12.8 56.8±11.8 – 0.110a 60.2±12.1 58.3±13.4 – 0.503a
Age <50 years, n (%) 34 (28.3) 37 (30.8) 0.89
(0.51–1.54)
0.671 11 (21.1) 23 (33.8) 0.52
(0.23–1.21)
0.127
Males, n (%) 65 (54.2) 65 (54.2) 1.00
(0.60–1.66)
1.000 32 (61.5) 33 (48.5) 1.70
(0.81–3.53)
0.156
BMI, kg/m2, mean±SD 25.7±3.89 24.4±3.35 – 0.010a 26.1±3.81 25.4±3.94 – 0.392a
BMI >25.0 kg/m2, n (%) 63 (52.5) 52 (43.3) 1.44
(0.87–2.40)
0.155 30 (57.7) 33 (48.5) 1.45
(0.70–2.99)
0.319
BMI >30.0 kg/m2, n (%) 16 (13.3) 5 (4.2) 3.54
(1.25–10.0)
0.012 9 (17.3) 7 (10.3) 1.82
(0.63–5.27)
0.263
Born in FVG region, n (%) 99 (82.5) 100 (83.3) 0.94
(0.48–1.85)
0.864 40 (76.9) 59 (86.8) 0.51
(0.20–1.32)
0.160
All 4 grand-parents born
in FVG region, n (%)
85 (70.8) 83 (69.2) 1.08
(0.62–1.88)
0.778 35 (67.3) 50 (73.5) 0.74
(0.34–1.63)
0.457
Elementary school (5 study
years), n (%)
17 (14.2) 8 (6.7) 2.31
(0.96–5.58)
0.057^ 10 (19.2) 7 (10.3) 2.07
(0.73–5.89)
0.164
Low high-school (8 study
years), n (%)
34 (28.3) 21 (17.5) 1.86
(1.01–3.45)
0.046 18 (34.6) 16 (23.5) 1.72
(0.77–3.83)
0.182
High-school (13 study
years), n (%)
54 (45.0) 42 (35.0) 1.52
(0.90–2.55)
0.114 21 (40.4) 33 (48.5) 0.72
(0.35–1.49)
0.374
University level (laurea
and/or master and/or
PhD), n (%)
15 (12.5) 49 (40.8) 0.21
(0.11–0.40)
<0.001 3 (5.8) 12 (17.6) 0.29
(0.08–1.07)
0.051^
Continued
Continued
Characteristics All melanomapatients (n=120) MetM (n=52) NMetM (n=68)
OR (CI) (MetM vs.
NMetM)
P (MetM vs.
NMetM)
TILsc absence, n (%) 41 (34.2) 23 (44.2) 18 (26.5) 2.20 (1.02–4.75) 0.042
Microsatellitosis, n (%) 4 (3.3) 3 (5.8) 1 (1.5) 4.10 (0.41–40.6) 0.315
Epithelioid variant, n (%) 30 (25.0) 19 (36.5) 11 (16.2) 2.98 (1.27–7.03) 0.011
Fusate variant, n (%) 12 (10.0) 7 (13.5) 5 (7.4) 1.96 (0.58–6.57) 0.269
Small cell variant, n (%) 2 (1.7) 0 (–) 2 (2.9) –b –b
More than 1 melanoma, n (%) 18 (15.0) 9 (17.3) 9 (13.2) 1.37 (0.50–3.74) 0.536
Additional non-melanoma skin
cancer, n (%) 18 (15.0) 7 (13.5) 11 (16.2) 0.81 (0.29–2.25) 0.680
Additional non-skin
cancer, n (%) 23 (19.2) 11 (21.2) 12 (17.6) 1.25 (0.50–3.12) 0.629
Melanoma familiarity 17 (14.2) 7 (13.5) 10 (14.7) 0.90 (0.32–2.57) 0.846
aTwo-tailed Mann-Whitney U-test.bOR uncountable because one or two of the compared groups had zero subject. cTILs, tumor infiltrating
lymphocytes. Significant differences were indicated in bold, tendencies were evidenced with superscript ^.
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Continued
Characteristics
All
melanoma
cases
n=120
Healthy
controls
n=120
OR (CI)
(melanomas
vs.
healthy
controls)
P
(melanomas
vs. healthy
controls)
MetM
n=52
NMetM
n=68
OR (CI)
(MetM vs.
NMetM)
P (MetM
vs.
NMetM)
Phototype 1 or 2, n (%) 71 (59.2) 31 (25.8) 4.16
(2.41–7.19)
<0.001 34 (65.4) 37 (54.4) 1.58
(0.75–3.33)
0.226
Total Body Nevi >50, n (%) 63 (52.5) 41 (34.2) 2.13
(1.27–3.58)
0.004 28 (53.8) 35 (51.5) 1.10
(0.53–2.27)
0.796
Easy tanner, n (%) 4 (3.3) 22 (18.3) 0.15
(0.05–0.46)
<0.001 0 (–) 4 (5.9) –b –b
Medium tanner, n (%) 50 (41.7) 71 (59.2) 0.49
(0.29–0.82)
0.007 22 (42.3) 28 (41.2) 1.05
(0.50–2.18)
0.901
Low tanner, n (%) 58 (48.3) 26 (21.7) 3.38
(1.93–5.94)
<0.001 27 (51.9) 31 (45.6) 1.29
(0.62–2.66)
0.491
No tanner, n (%) 8 (6.7) 2 (1.7) 4.21
(0.88–20.3)
0.053^ 3 (5.8) 5 (7.4) 0.77
(0.18–3.39)
1.000
Sunburns lifelong
≤5, n (%)
37 (30.8) 58 (48.3) 0.48
(0.28–0.81)
0.006 14 (26.9) 23 (33.8) 0.72
(0.33–1.59)
0.417
Sunburns lifelong
6–10, n (%)
21 (17.5) 28 (23.3) 0.70
(0.37–1.31)
0.262 12 (23.1) 9 (13.2) 1.97
(0.76–5.10)
0.160
Sunburns lifelong
>10, n (%)
51 (42.5) 27 (22.5) 2.55
(1.45–4.46)
0.001 21 (40.4) 30 (44.1) 0.86
(0.41–1.78)
0.682
Present-smoker, n (%) 13 (10.8) 20 (16.7) 0.61
(0.29–1.29)
0.189 5 (9.6) 8 (11.8) 0.80
(0.24–2.60)
0.707
≥20 years smoking among
present-smokers, n (%)
11 (84.6) 12 (60.0) 3.67
(0.64–21.1)
0.245 4 (80.0) 7 (87.5) 0.57
(0.03–11.8)
1.000
Years of smoking among
present-smokers, mean±SD
27.7±13.7 23.4±13.5 – 0.386a 25.4±7.96 29.1±16.7 – 0.558a
N. cigarettes/day among
present-smokers, mean±SD
14.4±9.99 9.83±6.26 – 0.234a 13.2±6.98 15.1±11.9 – 0.941a
Past-smoker, n (%) 46 (38.3) 28 (23.3) 2.04
(1.17–3.58)
0.012 23 (44.2) 23 (33.8) 1.55
(0.74–3.26)
0.245
≥20 years smoking among
past-smokers, n (%)
25 (54.3) 6 (21.4) 4.36
(1.49–12.8)
0.005 17 (73.9) 8 (34.8) 5.31
(1.50–18.8)
0.008
Years of smoking among
past-smokers, mean±SD
20.5±12.9 17.4±13.2 – 0.237a 24.5±13.9 16.4±10.6 – 0.039a
N. cigarettes/day among
past-smokers, mean±SD
14.9±10.5 16.0±13.2 – 0.964a 13.8±9.85 16.0±11.3 – 0.424a
Years quitting smoking
among past-smokers,
mean±SD
20.2±12.3 20.6±14.5 – 0.978a 20.0±13.0 20.3±11.9 – 0.895a
Quitted smoking before first
melanoma diagnosis among
past-smokers, n (%)
39 (84.8) – – – 19 (82.6) 20 (87.0) 0.71
(0.14–3.61)
1.000
Years of quitted smoking
before first melanoma
diagnosis, mean±SD
16.2±10.1 – – – 15.8±10.1 16.6±10.3 – 0.899
Ever-smoker, n (%) 59 (49.2) 48 (40.0) 1.45
(0.87–2.42)
0.153 28 (53.8) 31 (45.6) 1.39
(0.67–2.87)
0.370
Continued
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year  smokers  (17/36,  47.2%)  than  in  other  melanoma
patients (24/84, 28.6%), with OR=2.24, 95% CI=1.00–5.02,
and  P=0.048.  By  comparing  ≥20-year  smokers  with  the
remaining  melanoma  patients,  we  detected  significant
findings for males (OR=4.45, 95% CI=1.81–10.9, P=0.001),
stage III melanoma (OR=2.44, 95% CI=1.06–5.64, P=0.034),
and ulceration (OR=2.50, 95% CI=1.12–5.56, P=0.023).
Comparison of demographic, behavioral, and
environmental variables (Table 2)
Melanoma  patients  yielded  higher  mean  BMI  than  healthy
controls  (P=0.010),  and  the  number  of  obese  subjects  was
over  threefold  higher  (OR=3.54)  among  melanoma patients
than among healthy controls.
Melanoma patients more frequently presented phototype
1+2 (OR=4.16), total number of body nevi>50 (OR=2.13),
lifelong sunburns>10 (OR=2.55), and were more frequently
low tanners (OR=3.38) than healthy controls. MetM patients
did  not  differ  from  NMetM  patients  in  terms  of  these
characteristics.
Past  smokers  were  twofold  more  frequent  among
melanoma  patients  than  healthy  controls.  Among  past
smokers  smoking  for  ≥20  years  was  considerably  more
frequent  in  melanoma  patients  (OR=4.36)  than  healthy
controls and in MetM (OR=5.31) than NMetM patients. Past
smokers  with  MetM  showed  higher  average  number  of
smoking  years  than  NMetM  patients  (24.5±13.9  vs.
16.4±10.6 years; P=0.039). Among past smokers, melanoma
patients quitted smoking for an average of 16.2±10.1 years
before  melanoma  diagnosis,  and  differences  were  not
observed between MetM and NMetM patients.
Twenty or more years of smoking among lifelong smokers
and among all study subjects was a risk factor for melanoma
patients  vs.  healthy  controls  (OR=2.61  and  OR=2.43,
respectively) and for MetM vs. NMetM patients (OR=3.20
and OR=2.39, respectively).
The majority of melanoma patients and healthy controls
were daily coffee drinkers; no difference was noted among
groups even when considering those who consumed over
three cups of coffee per day.
Unadjusted comparisons of VDR-BsmI and
VDR-FokI genotypes alone or combined with
smoking and obesity (Table 3)
VDR-BsmI  and  VDR-FokI  genotypes  were  in  HWE  in
healthy controls and in melanoma patients. As expected, the
two SNPs were not in LD.
Homozygous  bb  genotype  was  more  frequent  among
MetM than among NMetM patients (OR=3.18). Intriguingly,
bb frequency was lower in NMetM patients than in healthy
controls (OR=0.40). Genotype bb combined with ≥20 years
of smoking was more frequent among all melanoma patients
than healthy  controls  (OR=4.78),  in  MetM than NMetM
patients  (OR=5.13),  and  in  MetM  patients  than  healthy
controls  (OR=9.18).  The  same  profile  was  observed  for
Bb+bb (b allele carriers) plus ≥20 years of smoking. Carriers
Continued
Characteristics
All
melanoma
cases
n=120
Healthy
controls
n=120
OR (CI)
(melanomas
vs.
healthy
controls)
P
(melanomas
vs. healthy
controls)
MetM
n=52
NMetM
n=68
OR (CI)
(MetM vs.
NMetM)
P (MetM
vs.
NMetM)
≥20 years smoking among
ever-smokers, n (%) 36 (61.0) 18 (37.5)
2.61
(1.19–5.72) 0.016 21 (75.0) 15 (48.4)
3.20
(1.06–9.69) 0.036
Years of smoking among
ever-smokers, mean±SD 22.0±13.3 19.9±13.5 – 0.298
a 24.7±12.9 19.7±13.4 – 0.086^a
N. cigarettes/day, among
ever-smokers, mean±SD 14.8±10.3 13.4±11.2 – 0.335
a 13.7±9.29 15.8±11.2 – 0.451a
≥20 years ever-smokers
among all subjects, n (%) 36 (30.0) 18 (15.0)
2.43
(1.29–4.58) 0.005 21 (40.4) 15 (22.1)
2.39
(1.08–5.31) 0.030
Coffee drinker daily, n (%) 110 (91.7) 112 (93.3) 0.79(0.30–2.06) 0.624 46 (88.5) 64 (94.1)
0.48
(0.13–1.79) 0.327
Coffee cups/day >3, n (%) 20 (16.7) 17 (14.2) 1.21(0.60–2.45) 0.592 11 (21.1) 9 (13.2)
1.76
(0.67–4.62) 0.249
aTwo-tailed Mann-Whitney U-test. bOR uncountable because one of the compared group had zero subject. Significant differences were
indicated in bold, tendencies were evidenced with superscript ^.
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Table 3   VDR-BsmI and VDR-FokI genotypes alone or combined with smoking duration and obesity compared between 120 melanoma
cases and 120 healthy controls.
Single or
combined variable
Melanoma
cases
(n=120),
n (%)
Healthy
controls
(n=120),
n (%)
OR (CI), P
(Melanomas
vs.
healthy
controls)
MetM
(n=52),
n (%)
NMetM
(n=68),
n (%)
OR (CI), P
(MetM vs.
NMetM)
OR (CI), P
(MetM vs.
healthy
controls)
OR (CI), P
(NMetM vs.
healthy
controls)
BB 30 (25.0) 31 (25.8) 0.96
(0.53–1.71),
0.882
11 (21.2) 19 (27.9) 0.69
(0.30–1.62),
0.395
0.77
(0.35–1.68),
0.512
1.11
(0.57–2.17),
0.753
Bb 64 (53.3) 56 (46.7) 1.31
(0.79–2.17),
0.302
24 (46.2) 40 (58.8) 0.60
(0.29–1.24),
0.168
0.98
(0.51–1.88),
0.951
1.63
(0.89–2.98),
0.109
bb 26 (21.7) 33 (27.5) 0.73
(0.40–1.32),
0.294
17 (32.7) 9 (13.2) 3.18
(1.28–7.91),
0.010
1.28
(0.63–2.59),
0.491
0.40
(0.18–0.90),
0.024
BB+Bb (B allele) 94 (78.3) 87 (72.5) 1.37
(0.76–2.48),
0.294
35 (67.3) 59 (86.8) 0.31
(0.13–0.78),
0.010
0.78
(0.39–1.58),
0.491
2.49
(1.11–5.58),
0.024
Bb+bb (b allele) 90 (75.0) 89 (74.2) 1.04
(0.58–1.87),
0.882
41 (78.8) 49 (72.1) 1.44
(0.62–3.38),
0.395
1.30
(0.59–2.83),
0.512
0.90
(0.46–1.75),
0.753
bb plus ≥20 years
ever-smoking
9 (7.5) 2 (1.7) 4.78
(1.01–22.6),
0.031
7 (13.5) 2 (2.9) 5.13
(1.02–25.8),
0.039
9.18
(1.84–45.8),
0.004
1.79
(0.25–13.0),
0.621
Bb+bb plus ≥20 years
ever-smoking
28 (23.3) 14 (11.7) 2.30
(1.14–4.64),
0.017
18 (34.6) 10 (14.7) 3.07
(1.27–7.41),
0.011
4.01
(1.80–8.90),
<0.001
1.30
(0.55–3.12),
0.549
bb plus BMI
>30 kg/m2
4 (3.3) 0 (–) –a 3 (5.8) 1 (1.5) 4.10
(0.41–40.6),
0.315
–a –a
Bb+bb plus BMI
>30 kg/m2
13 (10.8) 4 (3.3) 3.52
(1.11–11.1),
0.024
8 (15.4) 5 (7.4) 2.29
(0.70–7.47),
0.161
5.27
(1.51–18.4),
0.008
2.30
(0.60–8.88),
0.288
Bb+bb plus ≥20 years
ever-smoking, and plus
BMI >30 kg/m2
9 (7.5) 1 (0.8) 9.65
(1.20–77.4),
0.010
8 (15.4) 1 (1.5) 12.2
(1.47–101),
0.010
21.6
(2.63–178),
<0.001
1.78
(0.11–28.9),
1.00
FF 47 (39.2) 54 (45.0) 0.79
(0.47–1.31),
0.360
17 (32.7) 30 (44.1) 0.61
(0.29–1.30),
0.204
0.59
(0.30–1.17),
0.132
0.96
(0.53–1.76),
0.907
Ff 60 (50.0) 50 (41.7) 1.40
(0.84–2.33),
0.195
29 (55.8) 31 (45.6) 1.50
(0.73–3.11),
0.269
1.76
(0.91–3.40),
0.088^
1.17
(0.64–2.14),
0.602
ff 13 (10.8) 16 (13.3) 0.79
(0.36–1.72),
0.552
6 (11.5) 7 (10.3) 1.14
(0.36–3.61),
0.828
0.85
(0.31–2.31),
0.746
0.75
(0.29–1.91),
0.541
FF+ff (F allele) 107 (89.2) 104 (86.7) 1.27
(0.58–2.76),
0.552
46 (88.5) 61 (89.7) 0.88
(0.28–2.79),
0.828
1.18
(0.43–3.21),
0.746
1.34
(0.52–3.44),
0.541
Ff+ff (f allele) 73 (60.8) 66 (55.0) 1.27
(0.76–2.12),
0.360
35 (67.3) 38 (55.9) 1.62
(0.77–3.45),
0.204
1.68
(0.85–3.33),
0.132
1.04
(0.57–1.89),
0.907
Continued
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of b allele (Bb+bb) who were obese showed increased risk for
all melanomas (OR=3.52 for melanoma patients vs. healthy
controls)  and  MetM  (OR=5.27  for  MetM  vs.  healthy
controls). Notably, the combination of three parameters, i.e.,
Bb+bb  genotype  plus  ≥20  years  of  smoking  plus  obesity
yielded  high  ORs  for  all  melanoma  patients  vs.  healthy
controls (OR=9.65), MetM vs. NMetM patients (OR=12.2),
and MetM patients vs. healthy controls (OR=21.6).
As shown in Table 3,  VDR-FokI genotype FF, Ff, and ff
frequencies  did  not  differ  among  groups.  However,
heterozygous Ff had a tendency to be more frequent among
MetM patients than healthy controls (OR=1.76; P=0.088).
Notably, Ff genotype combined with ≥20 years of smoking
acted as risk factor for all melanoma patients (OR=3.04 for
melanoma patients vs. healthy controls) and MetM patients
(OR=4.84 for MetM patients vs. healthy controls). Carriers of
f  allele  (i.e.,  Ff+ff)  combined  with  ≥20  years  of  smoking
posed  risk  for  all  melanoma  patients  (OR=3.08  for
melanoma  patients  vs.  healthy  controls)  and  for  MetM
(OR=5.00  for  MetM  patients  vs.  healthy  controls,  and
OR=2.66  for  MetM  vs.  NMetM  patients).  Ff  genotype
combined with obesity exhibited OR=4.78 for all melanoma
patients vs. healthy controls and OR=6.28 for MetM patients
vs. healthy controls. Finally, obese carriers of Ff+ff presented
an  increased  risk  for  all  melanomas  (OR=6.56  for  all
melanoma  patients  vs.  healthy  controls)  and  for  MetM
(OR=9.18 for MetM patients vs. healthy controls). Notably,
only  6  out  of  240  study  subjects  showed  the  triple
combination of Ff+ff genotype, ≥20 years of smoking, and
obesity, and they were all MetM patients.
Comparisons of VDR-BsmI and VDR-FokI
genotypes, smoking, and obesity alone or their
combinations (Table 4)
As shown in Table  4,  by comparing all  120 melanoma cases
vs.  120  healthy  controls,  four  variables  including  the
parameter ≥20 years of ever smoking among all subjects were
significant  after  multivariate  analysis  of  type  1  confounders
(including  gender  and  age):  ≥20  years  of  smoking  alone
(OR=2.19),  or  plus  Bb+bb  (OR=2.08),  plus  Ff  (OR=2.77),
and  plus  Ff+ff  (OR=2.86)  genotype.  However,  all  those
differences became not significant adding more confounding
factors  by  analysis  of  type  2  confounders.  Multivariate
analysis  of  type  2  confounders  revealed  that  five  variables,
including obesity, were all risk factors for melanoma patients
vs. healthy controls, and they were as follows: BMI>30 kg/m2
alone  (OR=5.28),  or  plus  Bb+bb  (OR=4.35),  plus  Ff
(OR=6.91),  and  plus  Ff+ff  (OR=8.89)  genotype,  and  triple
combination  of  Bb+bb,  ≥20  years  of  smoking,  and  obesity
(OR=12.0).
Comparison of MetM patients vs healthy controls revealed
Continued
Single or
combined variable
Melanoma
cases
(n=120),
n (%)
Healthy
controls
(n=120),
n (%)
OR (CI), P
(Melanomas
vs.
healthy
controls)
MetM
(n=52),
n (%)
NMetM
(n=68),
n (%)
OR (CI), P
(MetM vs.
NMetM)
OR (CI), P
(MetM vs.
healthy
controls)
OR (CI), P
(NMetM vs.
healthy
controls)
Ff plus ≥20 years
ever-smoking
19 (15.8) 7 (5.8) 3.04
(1.23–7.52),
0.013
12 (23.1) 7 (10.3) 2.61
(0.95–7.21),
0.057^
4.84
(1.78–13.2),
0.001
1.85
(0.62–5.53),
0.263
Ff+ff plus ≥20 years
ever-smoking
24 (20.0) 9 (7.5) 3.08
(1.37–6.95),
0.005
15 (28.8) 9 (13.2) 2.66
(1.06–6.69),
0.034
5.00
(2.02–12.4),
<0.001
1.88
(0.71–4.99),
0.199
Ff plus BMI
>30 kg/m2
9 (7.5) 2 (1.7) 4.78
(1.01–22.6),
0.031
5 (9.6) 4 (5.9) 1.70
(0.43–6.68),
0.499
6.28
(1.18–33.5),
0.027
3.69
(0.66–20.7),
0.191
Ff+ff plus BMI
>30 kg/m2
12 (10.0) 2 (1.7) 6.56
(1.43–30.0),
0.006
7 (13.5) 5 (7.4) 1.96
(0.58–6.57),
0.269
9.18
(1.84–45.8),
0.004
4.68
(0.88–24.8),
0.101
Ff+ff plus ≥20 years
ever-smoking, and plus
BMI >30 kg/m2
6 (5.0) 0 (–) –a 6 (11.5) 0 (–) –a –a –a
aOR uncountable because one or two of the compared groups had zero subject. Significant differences were indicated in bold, tendencies
were evidenced with superscript ^.
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that combination of Bb+bb and ≥20 years of smoking was
significant  (OR=3.29)  after  adjustment  of  type  1
confounders, but became a tendency after adjustment of type
2  confounders.  By  contrast,  eight  other  variables  were
significant after both multivariate analyses of types 1 and 2
confounders. Specifically, by analysis of type 2 confounders,
the following significant findings were observed: ≥20 years of
smoking alone (OR=2.46) or combined with bb (OR=6.99),
Ff (OR=3.69), and Ff+ff (OR=3.92) genotype; and obesity
alone (OR=7.74) or combined with Bb+bb (OR=6.55), Ff
(OR=14.6), and Ff+ff (OR=17.8) genotype. Notably, triple
combination of Bb+bb, ≥20 years of smoking, and obesity
resulted in type 2-adjusted OR=22.7 for MetM patients vs
healthy controls.
Adjusted  comparisons  of  type  2  confounders  among
NMetM patients vs healthy controls revealed risk effects of
obesity (OR=3.69), Bb (OR=2.15), and BB+Bb (OR=3.30)
genotypes.
Comparisons of VDR-BsmI and VDR-FokI
genotypes, smoking, and obesity alone or their
combinations (Table 5)
Table  5  illustrates  comparison  of  MetM vs  NMetM patients
by  adjusted  analyses  of  types  1  to  5  confounders.  Smoking
duration of ≥20 years is a significant risk factor for MetM vs.
NMetM patients  (OR=2.26,  95% of CI=1.00–5.10,  P=0.050)
after  adjustment  for  obesity  (type  5  confounder).  However,
this risk factor became a tendency after extensive adjustments
(types  1  and  2  confounders).  Notably,  bb  genotype  showed
consistent  risky  adjusted  OR=3  for  MetM  vs.  NMetM  after
multivariate  analysis  of  types  1  to  5  confounders.
Consequently,  carriage  of  B  allele  (i.e.,  BB+Bb)  resulted  in
protective effects with respect to MetM. Significant threefold
increased  risk  for  MetM  vs.  NMetM  cases  was  observed  for
the  combination  of  Bb+bb  and  ≥20  years  of  smoking  after
adjustments for types 1, 2, and 5 confounders. Finally, triple
combination  of  Bb+bb,  ≥20  years  of  smoking,  and  obesity
showed  high  types  1  and  2-adjusted  ORs  (OR=10.7  and
OR=11.8,  respectively),  thus  attesting  for  gene-behavioral
effects among MetM patients.
Discussion
Our  study  was  carried  out  under  the  context  of  precision
medicine  approach  for  disease  treatment  and  prevention,
which considers individual variability in genes, environment,
and lifestyles42.
VDR-BsmI polymorphism
We  observed  similar  general  distribution  of  VDR-BsmI
genotypes  (BB  25.0%,  Bb  53.3%,  bb  21.7%)  among  all
Table 5   Association of ≥20 years of smoking, obesity, VDR-BsmI genotype, and VDR-FokI genotype as single or combined variables with
MetM (n=52) vs. NMetM (n=68), as evaluated by adjusted1,2,3,4,5 OR (CI)
Single or
combined
variable
Adjusted1 OR (CI),
P (MetM vs. NMetM)
Adjusted2 OR (CI),
P (MetM vs. NMetM)
Adjusted3 OR (CI),
P (MetM vs. NMetM)
Adjusted4 OR (CI),
P (MetM vs. NMetM)
Adjusted5 OR (CI),
P (MetM vs. NMetM)
≥20 years of
smoking
2.14 (0.92–4.94),
0.075^
2.14 (0.91–5.04),
0.081^ –
a –a 2.26 (1.00–5.10),0.050
BMI >30 kg/m2 1.60 (0.54–4.75),0.398
1.82 (0.58–5.77),
0.306 –
a 1.45 (0.48–4.37),
0.511 –
a
BB 0.77 (0.32–1.85),0.563
0.85 (0.35–2.05),
0.712
0.96 (0.34–2.77),
0.945
0.71 (0.30–1.69),
0.439
0.71 (0.30–1.66),
0.429
Bb 0.52 (0.24–1.12),0.094^
0.47 (0.21–1.02),
0.058^
0.45 (0.18–1.12),
0.086^
0.59 (0.28–1.24),
0.166
0.59 (0.28–1.23),
0.159
bb 3.28 (1.30–8.23),0.012
3.42 (1.34–8.76),
0.010
3.06 (1.05–8.88),
0.040
3.16 (1.25–7.99),
0.015
3.17 (1.27–7.91),
0.013
BB+Bb
(B allele)
0.30 (0.12–0.77),
0.012
0.29 (0.11–0.75),
0.010
0.33 (0.11–0.95),
0.040
0.32 (0.12–0.80),
0.015
0.31 (0.13–0.79),
0.013
Bb+bb
(b allele)
1.29 (0.54–3.09),
0.563
1.18 (0.49–2.87),
0.712
1.04 (0.36–2.98),
0.945
1.41 (0.59–3.35),
0.439
1.14 (0.60–3.32),
0.429
bb and ≥20
years of
smoking
4.38 (0.85–22.7),
0.078^
4.38 (0.82–23.3),
0.083^ –
a –a 4.73 (0.92–24.2),0.062^
Continued
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melanoma  patients  and  healthy  controls  (BB  25.8%,  Bb
46.7%,  bb  27.5%),  showing  agreement  with  other  case-
control  investigations16,20.  Notably,  a  threefold  higher
frequency  of  bb  genotype  was  observed  in  MetM  (32.7%)
compared  with  NMetM  cases  (13.2%);  this  value  ranged
from  significant  crude  OR=3.18  to  adjusted  ORs  ranging
from 3.06 to 3.42 after  considering several  confounders.  We
observed  that  B  carriers  (BB+Bb)  were  at  reduced  risk
comparing MetM vs. NMetM cases. However, B carriers were
at  increased  risk  when  comparing  NMetM  vs.  healthy
controls. Paradoxically, by comparison with healthy controls,
carriage  of  bb  genotype  posed  risk  to  MetM,  but  was
protective  for  NMetM  cases.  In  this  study,  distributions  of
genotypes in melanoma patients were similar with respect to
Bb  frequencies  of  those  observed  in  central  Italy  by
Santonocito et  al.15  in 101 melanoma patients (BB 9.9%, Bb
53.5%, bb 36.6%). The study indicated increased frequencies
of Bb and bb genotypes in melanoma patients compared with
healthy  controls  (BB  23.8%,  Bb  50.5%,  bb  25.7%)  and
demonstrated  an  association  between  VDR-BsmI  bb
genotype  and  increased  Breslow’s  thickness15,  a  parameter
that  is  consistently  associated  with  metastasis  and  poor
prognosis9.  A  meta-analysis17  showed  that  BsmI  B  allele  is
associated  with  reduced  melanoma  risk  with  OR=0.81  and
95%  CI=0.72–0.92.  A  large-scale  study  of  incidence  of
multiple  primary  melanoma  revealed  distribution  of  VDR-
BsmI,  with  values  of  BB  18.9%,  Bb  46.8%,  and  bb  34.2%,
among  patients  with  multiple  primary  melanomas  and  BB
Continued
Single or combined
variable
Adjusted1 OR (CI),
P (MetM vs. NMetM)
Adjusted2 OR (CI),
P (MetM vs. NMetM)
Adjusted3 OR (CI),
P (MetM vs. NMetM)
Adjusted4 OR (CI),
P (MetM vs. NMetM)
Adjusted5 OR (CI),
P (MetM vs. NMetM)
Bb+bb and ≥20
years of smoking
2.79 (1.07–7.22),
0.035
3.02 (1.13–8.09),
0.027 –
a –a 2.92 (1.16–7.32),0.023
bb plus BMI >30
kg/m2
3.22 (0.32–32.8),
0.323
3.37 (0.31–37.1),
0.320 –
a 2.92 (0.28–30.4),
0.371 –
a
Bb+bb plus BMI >30
kg/m2
1.94 (0.57–6.55),
0.285
2.10 (0.59–7.42),
0.250 –
a 1.66 (0.48–5.76),
0.426 -
a
Bb+bb plus ≥20
years of smoking,
and plus BMI >30
kg/m2
10.7 (1.26–90.7),
0.030
11.8 (1.33–105),
0.027 –
a –a –a
FF 0.65 (0.30–1.39),0.269
0.68 (0.31–1.49),
0.341
0.65 (0.26–1.61),
0.353
0.64 (0.30–1.39),
0.261
0.64 (0.30–1.37),
0.249
Ff 1.43 (0.68–2.99),0.342
1.46 (0.68–3.16),
0.332
1.01 (0.42–2.46),
0.974
1.48 (0.71–3.11),
0.296
1.48 (0.71–3.07),
0.291
ff 1.14 (0.35–3.72),0.830
0.98 (0.28–3.36),
0.970
3.32 (0.73–15.1),
0.120
1.05 (0.32–3.43),
0.937
1.07 (0.33–3.43),
0.915
FF+Ff (F allele) 0.88 (0.27–2.87),0.830
1.02 (0.30–3.53),
0.970
0.30 (0.07–1.37),
0.120
0.95 (0.29–3.11),
0.937
0.94 (0.29–3.02),
0.915
Ff+ff (f allele) 1.54 (0.72–3.29),0.269
1.46 (0.67–3.18),
0.341
1.54 (0.62–3.82),
0.353
1.55 (0.72–3.34),
0.261
1.56 (0.73–3.33),
0.249
Ff plus ≥20 years of
smoking
2.27 (0.79–6.48),
0.126
2.31 (0.79–6.72),
0.126 –
a –a 2.51 (0.91–6.97),0.077^
Ff+ff plus ≥20 years
of smoking
2.34 (0.89–6.13),
0.083^
2.34 (0.87–6.28),
0.093^ –
a –a 2.51 (0.99–6.39),0.054^
Ff plus BMI >30
kg/m2
1.46 (0.36–5.89),
0.593
1.59 (0.38–6.65),
0.521 –
a 1.52 (0.37–6.16),
0.559 –
a
Ff+ff plus BMI >30
kg/m2
1.73 (0.51–5.92),
0.382
1.81 (0.51–6.44),
0.357 –
a 1.67 (0.48–5.77),
0.421 –
a
1Adjusted  OR  (CI)  for  gender,  and  age.  2Adjusted  OR  for  gender,  age,  phototype  1+2,  total  body  nevi  >50,  and  >10  lifelong
sunburns.3Adjusted OR for trunk location, Breslow thickness, ulceration, mitosis >1, TILs absence, and epithelioid variant.4Adjusted OR for
≥20 years of smoking.5Adjusted OR for obesity (BMI >30 kg/m2).aNon calculated to avoid over-correction as described in "Methods".
Significant differences were indicated in bold, tendencies were evidenced with superscript ^.
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15.3%, Bb 47.7%, and bb 37.0% among patients  with single
primary  melanoma19.  A  recent  meta-analysis22  reported  a
15%  decrease  in  melanoma  risk  (pooled  OR=0.85,  95%
CI=0.76–0.94)  for  individuals  with  BB  or  Bb  genotype
compared with subjects featuring bb genotype.
In our study,  bb genotype combined with ≥20 years  of
smoking yielded adjusted OR=7 for MetM patients vs healthy
controls.  Bb+bb  (i.e.,  b  allele)  genotype  combined  with
obesity showed adjusted ORs from 4 to 7 for MetM patients
vs healthy controls.
Functional  effect  of  VDR-BsmI polymorphism remains
unclear39,41,43. This SNP is located in an intron sequence at
the 3’  end of VDR  gene.  Thus,  VDR-BsmI polymorphism
cannot  directly  change  the  protein  sequence  of  the  VDR
receptor. Some studies suggested that this SNP can influence
VDR-mRNA expression, thereby affecting its stability43. BsmI
site may be in LD with other truly relevant SNPs in VDR or
other genes14,15,44.
VDR-FokI polymorphism
In our study, VDR-FokI genotypes (FF 39.2%, Ff 50.0%, and
ff  10.8%  in  melanoma  cases  vs.  FF  45.0%,  Ff  41.7%,  and  ff
13.3%  in  healthy  controls)  were  not  associated  with
melanoma,  and  this  result  agrees  with  results  of  a  recent
meta-analysis21.  However,  we  noted  an  increased  risk  for
heterozygous  Ff  carriers  when  we  compared  MetM  vs.
NMetM cases. A Serbian study showed that compared with ff
genotype,  Ff  and  FF  were  associated  with  increased
melanoma  risk  (OR=3.03,  P=0.003;  OR=9.28,  P<0.001,
respectively)45.  In  general,  inconsistent  findings  were
reported  for  association  of  VDR-FokI  polymorphism  with
melanoma19,46.  In  one  meta-analysis20,  FokI  polymorphism
was  associated  with  an  overall  significantly  increased  risk  of
skin cancer (Ff vs. FF: OR=1.20, 95% CI=1.01–1.44; ff vs. FF:
OR=1.41,  95%  CI=1.08–1.84;  Ff+ff  vs.  FF:  OR=1.26,  95%
CI=1.04–1.53).  Another  meta-analysis22  claimed  that  f  allele
carriers  showed  an  18%  (pooled  OR=1.18,  95%
CI=1.07–1.29)  increased  risk  for  melanoma  compared  with
FF  homozygotes.  Notably,  in  our  study,  Ff+ff  (f  allele
carriers), when combined with ≥20 years of smoking or with
obesity,  exhibited  adjusted  OR=4  and  ORs  from  8  to  18,
respectively,  for  MetM  patients  vs.  healthy  controls.  The  f
allele codes for a 427 amino acids long VDR protein, and it is
considered less effective than the protein receptor coded by F
allele (424 amino acids long)40,41,43.
Smoking
Our study highlighted the crucial role of smoking duration in
susceptibility  to  cutaneous  melanoma  and  MetM.  Past-
smoking  for  ≥20  years  resulted  in  fourfold  risk  factor  for
melanoma  development  with  respect  to  healthy  controls
(OR=4.36) and fivefold risk factor for development of MetM
with  respect  to  NMetM  (OR=5.31),  whereas  ≥20  years  of
smoking  ever  in  life  yielded  OR=2.43  and  OR=2.39,
respectively.  We  also  observed  that  ≥20  years  of  ever  in  life
smoking  combined  with  certain  genetic  traits,  specifically,
with  bb,  Bb+bb  (b  allele  carriers),  Ff,  and  Ff+ff  (f  allele
carriers)  are  associated  with  significant  crude  ORs  ranging
from 4 to 9 for MetM cases vs healthy controls. Thus, smoke
effects  in  melanoma can be  modulated by  VDR activity  and
by the pleiotropic vitamin D endocrine system11-13,44. Further
studies  are  necessary  to  substantiate  this  significant  and
complex issue10,11,44.
Despite the large number of studies23,24,26-28,  results  on
association  of  smoking  with  melanoma  still  present
inconsistencies23. Some authors demonstrated risk effects of
smoking  in  melanoma10,23.  Using  multivariate  analysis
(adjusted  for  age,  sex,  site  of  primary  melanoma,  and
Breslow’s thickness),  a  recent study by Newton-Bishop et
al.10  revealed that  smoking duration at  diagnosis  (hazard
ratio=1.11, 95% CI=1.03–1.20, P=0.009) is associated with
risk of death from melanoma; and that lower vitamin D levels
and smoking are associated with ulceration (a well-known
poor  prognostic  factor)  of  primary  melanomas and poor
melanoma-specific  survival10.  We  also  noted  positive
association of ≥20 years of smoking with ulceration among
melanoma patients. We similarly observed association of ≥20
years of smoking with TIL absence, a finding that predisposes
in  our  and  other  studies  to  metastatic  melanoma8,9.
Conversely,  other  authors  showed inverse  relationship of
smoking with melanoma26-28. Multiple potential confounders
and  biases  can  explain  those  protective  associations  of
smoking23.  Our  present  findings  suggest  that  effects  of
smoking  duration  may  be  modulated  by  specific  genetic
traits.
In our study, past smokers among melanoma cases were
twofold more frequent than among healthy controls.  Our
findings  show  association  of  ≥20  years  of  smoking  with
increased risk of melanoma, indicating the need for detailed
assessment of  lifelong smoke duration.  We observed that
among past smokers, MetM patients smoked approximately
8 years longer than NMetM patients (24.5±13.9 vs. 16.4±10.6
years). Notably, we demonstrated that ≥20 years of smoking
serves as a two- to fivefold risk factor for MetM compared
with NMetM patients. Among study participants, over 80%
of past smokers with melanoma quit smoking before cancer
diagnosis,  with  an  average  of  16  years  before  melanoma
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development. This finding implies that exposure to smoke
carcinogens requires long periods to induce melanoma onset
and/or metastatic stage. Smoking effects long after smoking
discontinuation provide intriguing evidence, which implies
that some irreversible damages occur several years before first
melanoma diagnosis.  Long-lasting  variations  induced  by
smoking may include epigenetic changes in specific genes
that can remain, for example, differentially methylated after
smoking  cessation  (up  to  22  years,  as  demonstrated  by
Ambatipudi et al.47 and/or body accumulation of substances,
such as heavy metals, including radionuclides Lead-210 and
Polonium-2104 8 , 4 9 .  Explanation  for  such  smoking
phenomena require future detailed biological research and
human studies. A recent study on melanoma cells observed a
role  for  epigenetic  mechanisms  in  VDR-miRNAs
regulation50.
In our study, ≥20 years of smoking combined with carriage
of  b  allele  (Bb+bb)  showed adjusted  OR=3 for  MetM vs.
NMetM patients after extensive multivariate analyses. This
issue warrants further large-scale studies.
Coffee
We did not observe any significant findings in terms of coffee
consumption.  Thus,  our  data  do  not  confirm  protective
effects  of  coffee  consumption,  as  observed  by  other
researchers29.
Obesity
In our study, obesity presented an almost fourfold risk factor
for  melanoma  susceptibility  (OR=3.54),  similar  to  previous
population  studies  on  malignant  melanoma26,33.  Obesity
yielded  an  adjusted  OR=5  for  all  melanoma  patients  vs.
healthy  controls  and  adjusted  OR=8  for  MetM  patients  vs.
healthy controls. Obesity combined with Ff or Ff+ff exhibited
high  adjusted  OR=15  and  OR=18,  respectively,  for  MetM
patients  vs.  healthy controls.  BMI is  extensively  evaluated in
relation to several cancer types51. A large-cohort Italian study
demonstrated  that  BMI≥25  kg/m2  is  associated  with
Breslow’s thickness>1 mm among melanoma patients9.
We  are  the  first  research  group  to  assess  the  role  of
combination of obesity with specific VDR  genetic traits in
cutaneous melanoma. Interpretation of the association of
obesity with melanoma may feature a biological rationale.
Newton-Bishop  et  al.10  hypothesized  that  inflammation
associated with obesity can influence outcome of melanoma.
Some evidence also showed the genetic link between obesity
and pigmentation or hair color52.
Triple combination of VDR genetic traits,
smoking, and obesity
In  our  study,  the  highest  ORs  were  observed  after
combination of a VDR genetic trait (b allele carriers) and two
lifestyle  parameters,  i.e.,  Bb+bb  plus  ≥20  years  of  smoking
and  plus  obesity  by  comparing  all  melanoma  patients  vs.
healthy  controls  (OR=9.65),  MetM  patients  vs.  healthy
controls  (OR=21.6),  and  MetM  vs.  NMetM  patients
(OR=12.2).  All  data  remained  significant  according  to
multivariate analyses.
However, we failed to calculate ORs for analogous triple
combination comprising f allele carriers, because six study
subjects  with  Ff+ff  plus  ≥20  years  of  smoking  and  plus
obesity were all MetM patients. Further large-scale studies are
necessary for such assessments.
Roles of vitamin D in melanoma require further studies.
Melanoma cell culture and xenograft experiments in mice
highlighted that  vitamin D poses  tumoral  and metastasis
suppression effects53-55.  Virtually all  actions of  vitamin D
occur through VDR activation. Thus, any modification of
VDR activities induced by VDR  polymorphisms can affect
vitamin D functions13. Deletion of VDR results in increased
susceptibility  to  tumor  formation  and  reduces  ability  of
keratinocytes  to  clear  UVB-induced  DNA mutations13,56.
VDR can bind to thousands of VDREs on human genome
and up- or down-regulate hundreds of  genes.  Of interest,
recent  evidence  showed  a  crosstalk  between  VDR  and
immune factors57.  VDR cistrome analyses  suggested  that
altered expression of VDR in colon cancer changes actions of
VDR,  thus  affecting  patient  outcome58.  A  recent  study
showed that VDR genetic traits can modulate VDR protein
expression in excised human melanoma tissues, which might
have  implications  for  effects  of  vitamin  D  activity  on
melanoma cells59.
Thus,  future  research  should  focus  on  complex  gene
interactions and biological pathways related to vitamin D,
VDR, smoking, excessive fat, and environmental factors with
melanoma.  Improved  comprehension  of  biomolecular
pathways  will  support  further  progress  in  melanoma
management60.
Study limitations and strengths
Limitations  of  our  study  include  limited  number  of
melanomas  and  high  CIs  for  some  categorical  variables.
Nonetheless,  several  ORs  were  statistically  significant.
Analysis by data stratification for combined variables in some
cases  resulted  in  comparison  of  groups  with  less  than  10
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subjects.  Thus,  future  large-scale  studies  are  necessary  to
better assess the role of such combined variables. We focused
on white residents in northern Italy. Thus, our results cannot
be  generalized  to  populations  with  different  genetic
backgrounds.  By  contrast,  a  critical  strength  of  our  study  is
highly  defined  ethnic  background  of  subjects.  This  variable
bears  significance  in  genetic  studies.  Variability  in  racial
distribution  and  genetic  melanoma  susceptibility  among
(and  across)  different  countries  suggests  that  melanoma
studies  should  be  performed  in  restricted  and  well-
characterized  ethnic  groups7.  Another  strength  of  our  study
is the detailed reported information, including combinations
of genetic and lifestyle factors.
Conclusions
Treatment-resistant  metastatic  cancer  is  the most  significant
contributor  to  cancer  mortality  worldwide.  Thus,  better
understanding  of  factors  contributing  to  development  of
metastatic  cancer  may  increase  likelihood  of  future
improvements in patient management. Our data highlighted
that  in  terms  of  VDR  gene  alteration  by  SNPs,  vitamin  D
homeostasis  plays  roles  in  cutaneous  melanoma  and  MetM,
and  these  functions  are  further  enhanced  by  individual
smoking habits and BMI. Thus, our findings support a gene-
environment  contribution  to  development  of  malignant
melanoma,  suggesting  the  value  of  genetic  screening,
smoking cessation10, and excessive fat prevention51.
We  first  suggest  gene-environment  effects,  including
smoking  duration  and  obesity,  and  VDR  genetic
polymorphisms  with  cutaneous  malignant  melanoma  in
general  and  specifically  with  MetM.  Current  data  may
contribute  to  development  of  a  personalized/precision
management for melanoma patients. Such management may
include  screening  of  VDR  polymorphisms  and  detailed
assessment  of  smoking  habits  and  BMI.  Further
investigations are necessary to substantiate and extend our
findings to examine different ethnic groups and to identify
biological  pathways  related  to  vitamin  D,  smoking,  and
excessive fat, which influence skin cancers.
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